markets.financialcontent.com
Positivemarkets.financialcontent.com ·
stockstory 2026 5 6 collegium pharmaceutical coll q1 earnings report preview what to look for
TAX_FNCACT_ANALYSTSTAX_ECON_PRICETAX_FNCACT_PEERSECON_STOCKMARKET
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedThe article is a routine earnings preview for Collegium Pharmaceutical. No concrete commercial mechanism, supply disruption, or regulatory change is reported. The impact is company-specific and limited to the pharmaceutical sector. Weak mechanism / too early stage / no concrete channel.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Collegium Pharmaceutical to report Q1 earnings before market open on Thursday.
- Last quarter revenues were $205.4 million, up 12.9% YoY, but EPS missed estimates.
- Analysts expect Q1 revenue growth of 3.8%, a slowdown from 22.7% YoY growth.
- Peer Eli Lilly reported 55.5% revenue growth; Supernus Pharmaceuticals 38.6%.
- Current share price $35.31, average analyst target $54.17.